Drug Trial Radar · NCT06315738
Study to Assess the Safety, Tolerability, and Preliminary Efficacy of ST266 in Infants With Necrotizing Enterocolitis (NEC)
Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Aug 19, 2024
Primary completion
Jun 2029
Study completion Nov 2029
Sponsor
- Lead sponsor
- Noveome Biotherapeutics, formerly StemnionIndustry
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- Mar 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 weeks, up to 8 weeks
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to determine the safety and tolerability of two dose levels (0.5 mL/kg and 1.0 mL/kg) of once daily (QD) via IV route of administration of ST266 in treating patients with Bell's stage IIA or higher medical NEC by incidence of treatment emergent adverse events (TEAEs) and SAEs, with a secondary objective to assess preliminary efficacy of the same two dose levels (0.5 mL/kg and 1.0 mL/kg) of QD via IV route of administration of ST266 in treating patients with Bell's stage IIA or higher medical NEC.
Conditions
- Necrotizing Enterocolitis
Interventions
ST266Biological
Patients randomized to investigative drug product (ST266) will receive either 0.5 mL/kg or 1.0 mL/kg of ST266 QD in addition to Standard of Care treatment; Patients randomized to SOC will receive standard of care treatment only.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Tolerability endpoint: incidence of adverse eventsTime frame: From date of randomization through 24 months of age
- Safety and Tolerability endpoint: incidence of serious adverse eventsTime frame: From date of randomization through 24 months of age
- Safety and Tolerability endpoint: Changes in labs and vitals relative to disease progressionTime frame: From date of randomization through 24 months of age
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Arkansas Children's Hospital
Little Rock, Arkansas · Recruiting
University of Arkansas for Medical Sciences
Little Rock, Arkansas · Recruiting
Yale-New Haven Hospital
New Haven, Connecticut · Recruiting
BayCare Health System-St. Joseph's Women's Hospital
Tampa, Florida · Recruiting
NorthShore University-Evanston Hospital
Evanston, Illinois · Recruiting
Oklahoma Children's Hospital
Oklahoma City, Oklahoma · Recruiting
Penn State Health Milton S Hershey Medical Center/Penn State University College of Medicine
Hershey, Pennsylvania · Recruiting
University of Pittsburgh Medical Center Magee Womens Hospital
Pittsburgh, Pennsylvania · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.